Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring Pharmaceuticals Supports the Proclamation of November as Clostridioides difficile Infection Awareness Month in New Jersey and Minnesota
-In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11, 2021 – Ferring Pharmaceuticals and Rebiotix Inc., a Ferring Company, appreciate the support of New Jersey and Minnesota for officially recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month for the second year in a row. The proclamations from […]
-
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021
-New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including those with comorbidities previously excluded from clinical trials Analysis adds to the consistent body of efficacy and safety evidence for RBX2660 across prospective and retrospective analyses and varying patient populations Parsippany, NJ, USA – October 25, 2021 – Ferring Pharmaceuticals and […]
-
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C.Difficile Infection and IBD at ACG 2021
-Parsippany, NJ – October 18, 2021 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021. Eligibility criteria in CDI clinical trials often […]